ACRS News and Press, Aclaris Therapeutics Inc. From 08/03/22

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided...

Aclaris Therapeutics ( NASDAQ: ACRS ) appoints over 25 years of pharmaceutical industry experienced in both large and small companies Douglas Manion, M.D., FRCP ( C ), as President and Chief Operating Officer effective August 1, 2022. Dr. Manion will be ...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Aclaris Therapeutics (NASDAQ:ACRS) has appointed Gail Cawkwell, MD, PhD, as Chief Medical Officer, effective today. Most recently, she served as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance at Intercept Pharmaceuticals, Inc. Earlier this year, Aclaris falls on t...

WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will particip...

Studies suggest that index rebalancing anomalies generate excess risk-adjusted returns caused by stock index funds and institutional investors that benchmark the indexes. Four years of research including the most robust 2021 study come to a close on the annual June rebalancing and som...

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually...

Aclaris Therapeutics press release (NASDAQ:ACRS): Q1 GAAP EPS of -$0.31 beats by $0.09. Revenue of $1.45M (-18.5% Y/Y) misses by $0.22M. For further details see: Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M

Clinical Sites Activated for Phase 2b Trial of ATI-1777 April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on devel...

ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...